secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2026-09-28T21:27:17+00:00
Accession:  0001193125-26-405580
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Viking Therapeutics raises ~$548M via stock and 2.00% convertible notes offerings
--------------------------------------------------------------------------------

- Equity offering: 7,857,143 shares sold at $35.00/share, plus full exercise of the 1,178,571-share underwriter option; net proceeds ~$297.0M; closed Sept. 25, 2026.
- Debt offering: $225M of 2.00% convertible senior notes due Oct. 15, 2032, plus $33.75M option exercised in full; net proceeds ~$250.8M; interest payable semi-annually from April 15, 2027.
- Notes convert initially at ~$50.75/share (19.7044 shares per $1,000), a 45% premium to the $35.00 equity offering price; U.S. Bank Trust Company is trustee.
- Proceeds earmarked for clinical development and commercialization of VK2735, development of VK3019, and general R&D, working capital and corporate purposes.
- Notes callable on or after Oct. 22, 2029 if the stock exceeds 130% of the conversion price; cleanup redemption permitted if less than 15% of principal remains outstanding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000119312526405580/0001193125-26-405580-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000119312526405580/vktx-20260923.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-405580

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer